Literature DB >> 10817494

Can biological markers improve the management of breast cancer patients? Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10817494      PMCID： PMC2374516          DOI： 10.1054/bjoc.2000.1159

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  7 in total

1.  c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

Authors:  O Stål; S Sullivan; S Wingren; L Skoog; L E Rutqvist; J M Carstensen; B Nordenskjöld
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

Review 2.  Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance.

Authors:  D M Barnes; R R Millis; L V Beex; S M Thorpe; R E Leake
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

3.  Oestrogen-receptor status in management of breast cancer in UK.

Authors:  B J Mander; K Heal; A D Porushotham; G C Wishart
Journal:  Lancet       Date:  1998-07-04       Impact factor: 79.321

Review 4.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

5.  Oestrogen receptors and breast cancer.

Authors:  R M Elledge; C K Osborne
Journal:  BMJ       Date:  1997-06-28

Review 6.  Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.

Authors:  M Schmitt; N Harbeck; C Thomssen; O Wilhelm; V Magdolen; U Reuning; K Ulm; H Höfler; F Jänicke; H Graeff
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

7.  Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group.

Authors:  S Romain; C Lainé Bidron; P M Martin; H Magdelenat
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.